Journal article
Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial
B Temple, NT Toan, VTT Dai, K Bright, PV Licciardi, RA Marimla, CD Nguyen, DY Uyen, A Balloch, TN Huu, EK Mulholland
Lancet Infectious Diseases | ELSEVIER SCI LTD | Published : 2019
Abstract
Background: Few data are available to support the choice between the two currently available pneumococcal conjugate vaccines (PCVs), ten-valent PCV (PCV10) and 13-valent PCV (PCV13). Here we report a head-to-head comparison of the immunogenicity and reactogenicity of PCV10 and PCV13. Methods: In this parallel, open-label, randomised controlled trial, healthy infants from two districts in Ho Chi Minh City, Vietnam, were randomly allocated (in a 3:3:5:4:5:4 ratio), with use of a computer-generated list, to one of six infant PCV schedules: PCV10 in a 3 + 1 (group A), 3 + 0 (group B), 2 + 1 (group C), or two-dose schedule (group D); PCV13 in a 2 + 1 schedule (group E); or no infant PCV (control;..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
National Health and Medical Research Council of Australia, and Bill & Melinda Gates Foundation.